The challenge is not identifying demand, it is understanding what language consumers respond to, what outcomes they expect, and what makes them hesitate
From the 3348 subjects of the NESDA cohort, we aimed to select healthy controls (without any lifetime depressive/anxiety disorder) and those with a diagnosis of MDD at their baseline assessment
Whether GLP-1/GIP drugs can impact fibrosis remains an open basic and clinical question
On the same date, it became available exclusively to Consultants in Australia, New Zealand, Europe, the UK, Mexico, and Thailand
- poate sa Ssimuleze procesele metabolice i energetice
The company is years behind Novo and Lilly, whose weekly Zepbound shot is poised for blockbuster sales after gaining US approval last year